{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:46:44Z","timestamp":1793137604824,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,9,30]],"date-time":"2006-09-30T00:00:00Z","timestamp":1159574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2006,12,1]]},"DOI":"10.1007\/s00277-006-0180-7","type":"journal-article","created":{"date-parts":[[2006,9,29]],"date-time":"2006-09-29T13:37:09Z","timestamp":1159537029000},"page":"23-30","source":"Crossref","is-referenced-by-count":26,"title":["Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia"],"prefix":"10.1007","volume":"86","author":[{"given":"Vassilios","family":"Perifanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoleon","family":"Vyzantiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tziomalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Vakalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilia","family":"Garipidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Athanassiou-Metaxa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faidon","family":"Harsoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,9,30]]},"reference":[{"key":"180_CR1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.10834","volume":"48","author":"L Alvarez","year":"2003","unstructured":"Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F et al (2003) Serum osteoprotegerin and its ligand in Paget\u2019s disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 48:824\u2013828","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"180_CR2","first-page":"S441","volume":"15","author":"H Arrighi","year":"2000","unstructured":"Arrighi H, Khosla S, Melton LJ, Riggs BL, Bekker PJ, Dunstan CR (2000) The relationship between circulating osteoprotegerin and estrogen in postmenopausal women. J Bone Miner Res 15(Suppl 1):S441","journal-title":"J Bone Miner Res"},{"key":"180_CR3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.1999.14.9.1557","volume":"14","author":"JJ Body","year":"1999","unstructured":"Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J (1999) A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14:1557\u20131561","journal-title":"J Bone Miner Res"},{"key":"180_CR4","first-page":"631","volume":"86","author":"WS Browner","year":"2001","unstructured":"Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631\u2013637","journal-title":"J Clin Endocrinol Metab"},{"key":"180_CR5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1365-2265.1997.1951005.x","volume":"46","author":"L Cavallo","year":"1997","unstructured":"Cavallo L, Gurrado R, Gallo F, Zacchino C, De Mattia D, Tato L (1997) Growth deficiency in polytransfused beta-thalassaemia patients is not growth hormone dependent. Clin Endocrinol 46:701\u2013706","journal-title":"Clin Endocrinol"},{"key":"180_CR6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2265.2001.01198.x","volume":"54","author":"DC Chrysis","year":"2001","unstructured":"Chrysis DC, Alexandrides TK, Koromantzou E, Georgopoulos N, Vassilakos P, Kiess W et al (2001) Novel application of IGF-I and IGFBP-3 generation tests in the diagnosis of growth hormone axis disturbances in children with beta-thalassaemia. Clin Endocrinol 54:253\u2013259","journal-title":"Clin Endocrinol"},{"key":"180_CR7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbrc.2004.04.020","volume":"318","author":"J Cornish","year":"2004","unstructured":"Cornish J, Grey A, Callon KE, Naot D, Hill BL, Lin CQ et al (2004) Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. Biochem Biophys Res Commun 318:240\u2013246","journal-title":"Biochem Biophys Res Commun"},{"key":"180_CR8","first-page":"902","volume":"111","author":"R Dresner Pollack","year":"2000","unstructured":"Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW (2000) Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 111:902\u2013907","journal-title":"Br J Haematol"},{"key":"180_CR9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2265.1995.tb02920.x","volume":"43","author":"RJ Erdtsieck","year":"1995","unstructured":"Erdtsieck RJ, Pols HA, Valk NK, van Ouwerkerk BM, Lamberts SW, Mulder P et al (1995) Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Clin Endocrinol 43:557\u2013565","journal-title":"Clin Endocrinol"},{"key":"180_CR10","first-page":"226","volume":"5","author":"DL Faulkner","year":"1998","unstructured":"Faulkner DL, Young C, Hutchins D, McCollam JS (1998) Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 5:226\u2013229","journal-title":"Menopause"},{"key":"180_CR11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1359\/jbmr.2001.16.6.1015","volume":"16","author":"NR Fazzalari","year":"2001","unstructured":"Fazzalari NR, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM (2001) The ratio of messenger RNA levels of receptor activator of nuclear factor \u03baB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res 16:1015\u20131027","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"180_CR12","first-page":"SU454","volume":"15","author":"LJ Fraher","year":"2000","unstructured":"Fraher LJ, Watson PH, Kisiel M, Natale BV, Hodsman AB (2000) Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH(1\u201334). J Bone Miner Res 15(Suppl 1):SU454","journal-title":"J Bone Miner Res"},{"issue":"Suppl 3","key":"180_CR13","first-page":"49","volume":"58","author":"PP Geusens","year":"2002","unstructured":"Geusens PP, Boonen S (2002) Osteoporosis and the growth hormone-insulin-like growth factor axis. Horm Res 58(Suppl 3):49\u201355","journal-title":"Horm Res"},{"key":"180_CR14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-88-470-2183-9_6","volume-title":"Endocrine disorders in thalassaemia","author":"PJ Giardina","year":"1995","unstructured":"Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A, Gertner J et al (1995) Abnormal bone metabolism in thalassaemia. In: Ando S et al (eds) Endocrine disorders in thalassaemia. Springer, Berlin Heidelberg New York, pp 39\u201346"},{"key":"180_CR15","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1359\/jbmr.2002.17.11.1961","volume":"17","author":"D Hegedus","year":"2002","unstructured":"Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C et al (2002) Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res 17:1961\u20131967","journal-title":"J Bone Miner Res"},{"key":"180_CR16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1210\/jcem-52-3-393","volume":"52","author":"AC Herington","year":"1981","unstructured":"Herington AC, Werther GA, Mathews RN, Burger HG (1981) Studies on the possible mechanism for deficiency of non-suppressible insulin-like activity in thalassemia major. J Clin Endocrinol Metab 52:393\u2013398","journal-title":"J Clin Endocrinol Metab"},{"key":"180_CR17","first-page":"2355","volume":"85","author":"LC Hofbauer","year":"2000","unstructured":"Hofbauer LC, Heufelder AE (2000) The role of osteoprotegerin and receptor activator of NF-\u03baB ligand in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355\u20132363","journal-title":"J Clin Endocrinol Metab"},{"key":"180_CR18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/eje.0.1450681","volume":"145","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Schoppet M (2001) Serum measurement of osteoprotegerin. Clinical relevance and potential applications. Eur J Endocrinol 145:681\u2013683","journal-title":"Eur J Endocrinol"},{"key":"180_CR19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s001090100226","volume":"79","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243\u2013253","journal-title":"J Mol Med"},{"key":"180_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1359-6101(00)00030-7","volume":"12","author":"MC Horowitz","year":"2001","unstructured":"Horowitz MC, Xi Y, Wilson K, Kacena MA (2001) Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12:9\u201318","journal-title":"Cytokine Growth Factor Rev"},{"key":"180_CR21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.1998.01108.x","volume":"103","author":"CE Jensen","year":"1998","unstructured":"Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A et al (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103:911\u2013915","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"180_CR22","first-page":"101","volume":"49","author":"J Kapitola","year":"2000","unstructured":"Kapitola J, \u017d\u00e1k J, Lacinov\u00e1 Z, Justov\u00e1 V (2000) Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-1 levels in the rat. Physiol Res 49(Suppl 1):101\u2013106","journal-title":"Physiol Res"},{"key":"180_CR23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/emm.2002.21","volume":"34","author":"YH Kim","year":"2002","unstructured":"Kim YH, Kim GS, Jeong-Hwa B (2002) Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 34:145\u2013151","journal-title":"Exp Mol Med"},{"key":"180_CR24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/1381612013397807","volume":"7","author":"PJ Kostenuik","year":"2001","unstructured":"Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613\u2013635","journal-title":"Curr Pharm Des"},{"key":"180_CR25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165\u2013176","journal-title":"Cell"},{"key":"180_CR26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s001980170079","volume":"12","author":"A Lasco","year":"2001","unstructured":"Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 12:570\u2013575","journal-title":"Osteoporos Int"},{"key":"180_CR27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF03344015","volume":"25","author":"A Lasco","year":"2002","unstructured":"Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G, Frisina N (2002) Osteoporosis and beta-thalassemia major: role of the IGF-I\/IGFBP-III axis. J Endocrinol Investig 25:338\u2013344","journal-title":"J Endocrinol Investig"},{"key":"180_CR28","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/endo.140.8.6887","volume":"140","author":"SK Lee","year":"1999","unstructured":"Lee SK, Lorenzo JA (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140:3552\u20133561","journal-title":"Endocrinology"},{"key":"180_CR29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2265.1998.00470.x","volume":"48","author":"LC Low","year":"1998","unstructured":"Low LC, Postel-Vinay MC, Kwan EY, Cheung PT (1998) Serum growth hormone (GH) binding protein, IGF-I and IGFBP-3 in patients with beta-thalassaemia major and the effect of GH treatment. Clin Endocrinol 48:641\u2013646","journal-title":"Clin Endocrinol"},{"key":"180_CR30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2265.2003.01707.x","volume":"58","author":"P Mahachoklertwattana","year":"2003","unstructured":"Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R (2003a) Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. Clin Endocrinol 58:273\u2013279","journal-title":"Clin Endocrinol"},{"key":"180_CR31","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1210\/jc.2002-021548","volume":"88","author":"P Mahachoklertwattana","year":"2003","unstructured":"Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A et al (2003b) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 88:3966\u20133972","journal-title":"J Clin Endocrinol Metab"},{"key":"180_CR32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558\u2013567","journal-title":"J Clin Oncol"},{"key":"180_CR33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s001980200087","volume":"13","author":"N Morabito","year":"2002","unstructured":"Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A et al (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644\u2013649","journal-title":"Osteoporos Int"},{"key":"180_CR34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1359\/jbmr.040113","volume":"19","author":"N Morabito","year":"2004","unstructured":"Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M et al (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19:722\u2013727","journal-title":"J Bone Miner Res"},{"key":"180_CR35","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1359\/jbmr.1999.14.7.1182","volume":"14","author":"MG Murphy","year":"1999","unstructured":"Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D et al The MK-677 Study Group (1999) Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res 14:1182\u20131188","journal-title":"J Bone Miner Res"},{"key":"180_CR36","first-page":"1116","volume":"86","author":"MG Murphy","year":"2001","unstructured":"Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J et al MK-677\/Alendronate Study Group (2001) Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 86:1116\u20131125","journal-title":"J Clin Endocrinol Metab"},{"key":"180_CR37","first-page":"55","volume":"19","author":"C Ohlsson","year":"1998","unstructured":"Ohlsson C, Bengtsson BA, Isaksson OGP, Andreassen TT, Slootweg MC (1998) Growth hormone and bone. Endocr Rev 19:55\u201379","journal-title":"Endocr Rev"},{"key":"180_CR38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1359\/jbmr.2000.15.5.863","volume":"15","author":"JE Onyia","year":"2000","unstructured":"Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A et al (2000) In vivo demonstration that parathyroid hormone 1\u201338 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863\u2013871","journal-title":"J Bone Miner Res"},{"key":"180_CR39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00774-003-0435-5","volume":"21","author":"P Pennisi","year":"2003","unstructured":"Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21:402\u2013408","journal-title":"J Bone Miner Metab"},{"key":"180_CR40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New Engl J Med 346:653\u2013661","journal-title":"New Engl J Med"},{"key":"180_CR41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2265.2004.02006.x","volume":"60","author":"D Rucker","year":"2004","unstructured":"Rucker D, Ezzat S, Diamandi A, Khosravi J, Hanley DA (2004) IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin Endocrinol 60:491\u2013499","journal-title":"Clin Endocrinol"},{"key":"180_CR42","first-page":"773","volume":"11","author":"L Ruggiero","year":"1998","unstructured":"Ruggiero L, De Sanctis V (1998) Multicentric study on prevalency of fractures in transfusion-dependent thalassemic patients. J Pediatr Endocrinol Metab 11:773\u2013778","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"Suppl 2","key":"180_CR43","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/8756-3282(95)00203-P","volume":"17","author":"E Seeman","year":"1995","unstructured":"Seeman E, Tsalamandris C, Bass S, Pearce G (1995) Present and future of osteoporosis therapy. Bone 17(Suppl 2):23S\u201329S","journal-title":"Bone"},{"key":"180_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6823-3-4","volume":"3","author":"AA Shamshirsaz","year":"2003","unstructured":"Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M et al (2003) Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocrine Disorders 3:1\u20136","journal-title":"BMC Endocrine Disorders"},{"key":"180_CR45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309\u2013319","journal-title":"Cell"},{"key":"180_CR46","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1530\/eje.0.1380394","volume":"138","author":"AT Soliman","year":"1998","unstructured":"Soliman AT, El Banna N, Ansari BM (1998a) GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia. Eur J Endocrinol 138:394\u2013400","journal-title":"Eur J Endocrinol"},{"key":"180_CR47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0026-0495(98)90237-2","volume":"47","author":"AT Soliman","year":"1998","unstructured":"Soliman AT, El Banna N, Abdel Fattah M, El Zalabani MM, Ansari BM (1998b) Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 47:541\u2013548","journal-title":"Metabolism"},{"key":"180_CR48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/tropej\/45.6.327","volume":"45","author":"AT Soliman","year":"1999","unstructured":"Soliman AT, el Zalabany MM, Mazloum Y, Bedair SM, Ragab MS, Rogol AD et al (1999) Spontaneous and provoked growth hormone (GH) secretion and insulin-like growth factor I (IGF-I) concentration in patients with beta thalassaemia and delayed growth. J Trop Pediatr 45:327\u2013337","journal-title":"J Trop Pediatr"},{"key":"180_CR49","first-page":"3162","volume":"86","author":"P Szulc","year":"2001","unstructured":"Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD (2001) Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86:3162\u20133165","journal-title":"J Clin Endocrinol Metab"},{"key":"180_CR50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/eje.0.1480527","volume":"148","author":"H Valleala","year":"2003","unstructured":"Valleala H, Mandelin J, Laasonen L, Koivula MK, Risteli J, Konttinen YT (2003) Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. Eur J Endocrinol 148:527\u2013530","journal-title":"Eur J Endocrinol"},{"key":"180_CR51","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","volume":"291","author":"V Viereck","year":"2002","unstructured":"Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C et al (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680\u2013686","journal-title":"Biochem Biophys Res Commun"},{"key":"180_CR52","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2036.2003.01448.x","volume":"17","author":"C Tirpitz von","year":"2003","unstructured":"von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R et al (2003) Therapy of osteoporosis in patients with Crohn\u2019s disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 17:807\u2013816","journal-title":"Aliment Pharmacol Ther"},{"key":"180_CR53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-2141.2001.02549.x","volume":"112","author":"E Voskaridou","year":"2001","unstructured":"Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A et al (2001) Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 112:36\u201341","journal-title":"Br J Haematol"},{"key":"180_CR54","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1365-2141.2003.04657.x","volume":"123","author":"E Voskaridou","year":"2003","unstructured":"Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A et al (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123:730\u2013737","journal-title":"Br J Haematol"},{"key":"180_CR55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.2004.05143.x","volume":"127","author":"E Voskaridou","year":"2004","unstructured":"Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127:127\u2013139","journal-title":"Br J Haematol"},{"key":"180_CR56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2141.1998.01107.x","volume":"103","author":"B Wonke","year":"1998","unstructured":"Wonke B (1998) Bone disease in beta thalassaemia major. Br J Haematol 103:897\u2013901","journal-title":"Br J Haematol"},{"key":"180_CR57","unstructured":"World Health Organization Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. W.H.O. Technical Report Series, 843"},{"key":"180_CR58","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1359\/jbmr.1999.14.4.518","volume":"14","author":"K Yano","year":"1999","unstructured":"Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A et al (1999) Immunological characterization of circulating osteoprotegerin\/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518\u2013527","journal-title":"J Bone Miner Res"},{"key":"180_CR59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1359\/jbmr.2003.18.4.599","volume":"18","author":"M Zaidi","year":"2003","unstructured":"Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL (2003) Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 18:599\u2013609","journal-title":"J Bone Miner Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0180-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-006-0180-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0180-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:44:55Z","timestamp":1559036695000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-006-0180-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,30]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12,1]]}},"alternative-id":["180"],"URL":"https:\/\/doi.org\/10.1007\/s00277-006-0180-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,30]]}}}